EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 112.98

Change

-0.48 (-0.42)%

Market Cap

USD 0.70B

Volume

4.06K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.17 (+0.33%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.05 (+0.28%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.13 (+0.47%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.07 (+0.25%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.12 (-0.47%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.03 (+0.07%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

+0.02 (+0.01%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.18 (+0.34%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.60 (+0.59%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.00 (+0.52%)

USD 80.38B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.01% 44% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.01% 44% F 49% F
Trailing 12 Months  
Capital Gain 10.48% 39% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.48% 39% F 45% F
Trailing 5 Years  
Capital Gain 30.79% 57% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.79% 57% F 62% D
Average Annual (5 Year Horizon)  
Capital Gain 6.64% 54% F 53% F
Dividend Return 7.58% 58% F 56% F
Total Return 0.94% 63% D 44% F
Risk Return Profile  
Volatility (Standard Deviation) 8.48% 67% D+ 74% C
Risk Adjusted Return 89.31% 87% B+ 88% B+
Market Capitalization 0.70B 71% C- 63% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike